Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy
A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Hanmi Pharmaceutical Company Limited, completed.
Overview
Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy is a phase 2 interventional study registered as NCT02444819 by Hanmi Pharmaceutical Company Limited, with 33 participants recorded, started 2015-03 and reaching its primary completion in 2017-08. Interventions recorded: HM61713. Conditions recorded: Non Small Cell Lung Cancer.
Linked to the drug Olmutinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPhase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
Shares Hanmi Pharmaceutical, Olmutinib, Non-small-cell lung cancer and the tag pipeline.
- TrialOlmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA
Shares Olmutinib, Non-small-cell lung cancer and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialEfficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialHC010 in First-line PD-L1 Positive Advanced NSCLC Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.